Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma

The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

http://eon.businesswire.com/news/eon/20130724005252/en/Verastem-Receives-Orphan-Drug-Designation-U.S.-FDA